S
Suzhou Yikesai Biotechnology
Innovative biotechnologies enhancing antiviral responses and advancing bovine serum products for research and development
About Suzhou Yikesai Biotechnology
Excellbio operates in the biotechnology sector, specializing in the development of advanced biotechnologies that enhance antiviral responses and provide high-quality bovine serum products for research and development. The company serves a diverse range of clients, including academic institutions, pharmaceutical companies, and research laboratories. Excellbio's core business model revolves around the production and sale of specialized bovine serum products, such as Fetal Bovine Serum (FBS), which are essential for cell culture and other research applications. The company generates revenue through direct sales of these products, leveraging its expertise in biotechnology to offer superior quality and reliability. Excellbio's market is primarily focused on the life sciences and pharmaceutical industries, where there is a constant demand for high-quality research materials. The company's innovative approach to enhancing antiviral responses through ubiquitin ligase RNF5 regulation further positions it as a leader in the field of biotechnology.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2023 | $14M | $55M | Pu En Zerui · Shenzhen Investment Holdings · ABC International Holdings · Jinpu Muhe | ↗ |
| SERIES B✓Equity / VC | Feb 2023 | $14M | $55M | AAMA Angel Fund · Haiwang Capital · Chentao Capital · Shanghai Science and Technology Investment | ↗ |
Growth signals
Latest recorded traffic for Suzhou Yikesai Biotechnology is 2.8K monthly website visits, up 4566.7% over the last three months. Suzhou Yikesai Biotechnology's team grew 11.1% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Yikesai Biotechnology in the Huangpu ecosystem
The Suzhou Yikesai Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Matrix Partners China
AAMA Angel Fund- HCHaiwang Capital
- CCChentao Capital
- SIShanghai Science and Technology Investment
CICC- PZPu En Zerui
- SHShenzhen Investment Holdings
ABC International Holdings- JMJinpu Muhe
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Yikesai Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Yikesai Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.